Breaux Castleman
CIK 1335073 · last filed 2020-07-06
Breaux Castleman is a corporate insider who has filed 31 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for IONS, was dated Jul 6, 2020. Across all open-market trades the lifetime net is −$542.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 11 SEC filings were submitted jointly with IONIS PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IONS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
IRVINE, CA 92618
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IONS | Director | 18,516 | $40.15 | $743.4K | -$600.0K | 6 | 2020-07-06 |
| USMD | Director | 14,491 | $29.22 | $423.4K | $0 | 6 | 2016-01-07 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Director | 3,481 | — | — | $0 | 4 | 2015-07-02 |
| STRATA Skin Sciences, Inc. (MELA) Delisted | Director | 117,238 | — | — | $57.6K | 14 | 2011-12-12 |
Recent Filings
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-06 | IONS | Mixed | +4,000 | $0 | EDGAR |
| 2020-06-29 | IONS | Mixed | — | -$333.4K | EDGAR |
| 2019-07-03 | IONS | Mixed | +2,889 | $0 | EDGAR |
| 2018-07-03 | IONS | Mixed | +2,667 | $0 | EDGAR |
| 2017-07-03 | IONS | Mixed | +3,406 | $0 | EDGAR |
| 2016-10-04 | — | Disp (D) | −14,491 | $0 | |
| 2016-07-06 | IONS | Mixed | +2,740 | $0 | EDGAR |
| 2016-01-07 | USMD | Grant (A) | +2,099 | $16.8K | EDGAR |
| 2015-10-09 | USMD | Grant (A) | +5,290 | $47.5K | EDGAR |
| 2015-07-02 | IONIS PHARMACEUTICALS INC (ISIS) Delisted | Mixed | +2,074 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.